活性重组蛋白Human Chorionic somatomammotropin hormone 1 Choriomammotropin CSH1 Protein　重组蛋白

种属

Human

表达宿主

HEK293 cells

描述

Recombinant Human Chorionic somatomammotropin hormone 1/Choriomammotropin/CSH1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val27-Phe217) of human Chorionic somatomammotropin hormone 1/Choriomammotropin/CSH1 (Accession #NP_001308.1) fused with a 6×His tag at the C-terminus.

标签

C-6His

纯度

> 97% by SDS-PAGE.

内毒素

<0.001EU/μg

制剂

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

储存

Store the lyophilized protein at -20°C to -80°C for 12 months.
After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。

复溶

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid votex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。

背景信息

Chorionic somatomammotropin hormone, also known as Choriomammotropin, Lactogen, Placental lactogen and CSH1, is a secreted protein which belongs to thesomatotropin / prolactin family. CSH1 is produced only during pregnancy and is involved in stimulating lactation, fetal growth and metabolism. Does not interact with GHR but only activates PRLR through zinc-induced dimerization. The CSH1 gene is member of the GH gene cluster on 17q, which consists of two growth hormone genes and three CSH genes. Genomic alterations in the GH cluster are well known, causing different phenotypes depending on the size of the deletion and the genes involved. The increased prevalence of hemizygosity of CSH1 in population in comparison to controls indicates a role for CSH1 haploinsufficiency in the etiology of growth retardation. Investigation of CSH1 deletions in further SRS and growth retarded patients will enable us to establish under which circumstances haploinsufficiency of CSH1 is likely to result in clinical changes.

基因ID

1442

Swiss Prot

P0DML2

别名

PL; CSA; CS-1; CSMT; GHB3; hCS-1; hCS-A